 Phase intravenous infusions new derivative camptothecin treatment advanced non-small-cell lung cancer carbonyloxy-camptothecin novel camptothecin derivative clinical evaluation broad spectrum antitumor activity animal models unique inhibitory effects mammalian DNA topoisomerase Seventeen patients advanced non-small-cell lung cancer weekly dose levels weekly doses patients total weekly doses patients dose-limiting toxic effects myelosuppression unpredictable diarrhea Gastrointestinal toxic effects severe standard therapy patients Interpatient variability toxic effects substantial deaths pharmacokinetic parameters major metabolite untreated patients doses partial responses months maximum tolerated dose schedule starting dose phase II studies schedule dose intensity double dose intensity possible once-a-month schedule careful supervision gastrointestinal toxic effects myelosuppression indispensable wide individual differences drug tolerance